Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly sold 4,928 shares of common stock at $2.67 per share on July 28, 2026. The sale was executed under a durable Rule 10b5-1 automatic sales plan to cover tax withholding from restricted stock units vesting on July 24, 2026 and was not a discretionary trade. Following this transaction, Burkly directly held 62,369 shares of Editas Medicine common stock.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Editas Medicine, Inc.. BlackRock reported beneficial ownership of 8,355,588 shares, representing 4.97% of Editas Medicine’s outstanding common stock.
BlackRock reported sole voting power over 8,226,483 shares and sole dispositive power over 8,355,588 shares, with no shared voting or dispositive power. Various underlying persons have rights to dividends or sale proceeds, but no single person has more than five percent of Editas Medicine’s outstanding common shares.
Linda C. Burkly has notified of an intention to sell up to 5,500 shares of Common Stock of Editas Medicine on or after 07/27/2026 on NASDAQ. The planned sale relates to shares associated with Restricted Stock Unit vesting, with 11,292 shares shown as acquired from the issuer as equity compensation on 07/24/2026.
During the prior three months, Burkly sold 731 shares of Common Stock for $1,974.50 on 06/03/2026. These details outline upcoming and recent insider share transactions but do not themselves state any change in company operations or financial results.
Editas Medicine, Inc. director Bernadette Connaughton received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share, are scheduled to vest in full on June 17, 2027, and expire on June 16, 2036. Following this compensation award, she holds 51,700 derivative securities directly, with no open-market buy or sell reported.
Editas Medicine director Jessica Hopfield received a new stock option grant. On June 17, 2026, she was awarded options to acquire 51,700 shares of Editas Medicine common stock at an exercise price of $2.55 per share.
The option is scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this grant, she holds options covering 51,700 shares directly as reported in this filing.
Editas Medicine director Andrew Hirsch received a stock option grant as part of his compensation. The award covers 51,700 options to buy Editas Medicine common stock at an exercise price of $2.55 per share. The option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027, with an expiration date of June 16, 2036. Following this grant, Hirsch holds 51,700 stock options directly, and there were no open‑market stock purchases or sales reported in this filing.
Editas Medicine, Inc. director David Scadden received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and expire on June 16, 2036. They were granted on June 17, 2026 and are scheduled to vest in full on June 17, 2027. Following this grant, Scadden holds 51,700 stock options directly.
Editas Medicine director Elliott M. Levy received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and were granted on June 17, 2026. They are scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this award, Levy holds 51,700 derivative securities directly.
Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Connaughton received 28,660,181 votes for and 10,789,549 withheld, while Levy received 37,095,058 votes for and 2,354,672 withheld, in each case with 26,404,190 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 32,914,258 votes for, 6,322,885 against, 212,587 abstentions, and 26,404,190 broker non-votes. In addition, they ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 64,686,839 votes for, 774,471 against, and 392,610 abstentions.
Editas Medicine, Inc. senior vice president and chief financial officer Amy Parison reported an open-market sale of 464 shares of common stock on June 3, 2026 at a weighted average price of $2.7010 per share. According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 7, 2022 and was made to satisfy tax withholding obligations arising from vesting of restricted stock units on June 2, 2026, rather than as a discretionary trade. Following this transaction, she directly holds 14,970 shares of Editas Medicine common stock.